NYSE: MTD
Mettler Toledo
Health Care · Laboratory Analytical Instruments
52-week range
$1,023.05$1,728.66
Stock price
Market cap
At each fiscal year end, then the latest quarter end: closing price × shares outstanding.Figures shown are for the trailing 12 months to Jun 30, 2026. Hover or tap a column for another year.$25.6B
Show tableHide table
| Period | Market cap |
|---|---|
| FY2016, ended Dec 31, 2016 | $10.9B |
| FY2017, ended Dec 31, 2017 | $15.8B |
| FY2018, ended Dec 31, 2018 | $14.0B |
| FY2019, ended Dec 31, 2019 | $19.1B |
| FY2020, ended Dec 31, 2020 | $26.7B |
| FY2021, ended Dec 31, 2021 | $38.7B |
| FY2022, ended Dec 31, 2022 | $32.0B |
| FY2023, ended Dec 31, 2023 | $26.1B |
| FY2024, ended Dec 31, 2024 | $25.6B |
| FY2025, ended Dec 31, 2025 | $28.3B |
| Trailing 12 months to Jun 30, 2026 (through Q2 FY2026) | $25.6B |
Revenue
By fiscal year, then the trailing 12 months.Figures shown are for the trailing 12 months to Jun 30, 2026. Hover or tap a column for another year.$4.13B
Show tableHide table
| Period | Revenue |
|---|---|
| FY2016, ended Dec 31, 2016 | $2.51B |
| FY2017, ended Dec 31, 2017 | $2.73B |
| FY2018, ended Dec 31, 2018 | $2.94B |
| FY2019, ended Dec 31, 2019 | $3.01B |
| FY2020, ended Dec 31, 2020 | $3.09B |
| FY2021, ended Dec 31, 2021 | $3.72B |
| FY2022, ended Dec 31, 2022 | $3.92B |
| FY2023, ended Dec 31, 2023 | $3.79B |
| FY2024, ended Dec 31, 2024 | $3.87B |
| FY2025, ended Dec 31, 2025 | $4.03B |
| Trailing 12 months to Jun 30, 2026 (through Q2 FY2026) | $4.13B |
Net income and free cash flow
By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.Figures shown are for the trailing 12 months to Jun 30, 2026. Hover or tap a column for another year.Show tableHide table
| Period | Net income | Free cash flow |
|---|---|---|
| FY2016, ended Dec 31, 2016 | $384M | $337M |
| FY2017, ended Dec 31, 2017 | $376M | $389M |
| FY2018, ended Dec 31, 2018 | $513M | $422M |
| FY2019, ended Dec 31, 2019 | $561M | $506M |
| FY2020, ended Dec 31, 2020 | $603M | $632M |
| FY2021, ended Dec 31, 2021 | $769M | $801M |
| FY2022, ended Dec 31, 2022 | $873M | $738M |
| FY2023, ended Dec 31, 2023 | $789M | $861M |
| FY2024, ended Dec 31, 2024 | $863M | $864M |
| FY2025, ended Dec 31, 2025 | $869M | $849M |
| Trailing 12 months to Jun 30, 2026 (through Q2 FY2026) | $906M | $864M |
Cash and cash equivalents
At each fiscal year end, then the latest quarter end.Figures shown are for the trailing 12 months to Jun 30, 2026. Hover or tap a column for another year.$51.4M
Show tableHide table
| Period | Cash and cash equivalents |
|---|---|
| FY2016, ended Dec 31, 2016 | $159M |
| FY2017, ended Dec 31, 2017 | $149M |
| FY2018, ended Dec 31, 2018 | $178M |
| FY2019, ended Dec 31, 2019 | $208M |
| FY2020, ended Dec 31, 2020 | $94.3M |
| FY2021, ended Dec 31, 2021 | $98.6M |
| FY2022, ended Dec 31, 2022 | $96.0M |
| FY2023, ended Dec 31, 2023 | $69.8M |
| FY2024, ended Dec 31, 2024 | $59.4M |
| FY2025, ended Dec 31, 2025 | $66.9M |
| Trailing 12 months to Jun 30, 2026 (through Q2 FY2026) | $51.4M |
Total debt
At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.Figures shown are for the trailing 12 months to Jun 30, 2026. Hover or tap a column for another year.$2.04B
Show tableHide table
| Period | Total debt |
|---|---|
| FY2016, ended Dec 31, 2016 | $875M |
| FY2017, ended Dec 31, 2017 | $960M |
| FY2018, ended Dec 31, 2018 | $985M |
| FY2019, ended Dec 31, 2019 | $1.24B |
| FY2020, ended Dec 31, 2020 | $1.28B |
| FY2021, ended Dec 31, 2021 | $1.58B |
| FY2022, ended Dec 31, 2022 | $1.91B |
| FY2023, ended Dec 31, 2023 | $1.89B |
| FY2024, ended Dec 31, 2024 | $1.83B |
| FY2025, ended Dec 31, 2025 | $2.09B |
| Trailing 12 months to Jun 30, 2026 (through Q2 FY2026) | $2.04B |
Shares outstanding
At each fiscal year end, then the latest quarter end, adjusted for splits. Down 22.8% since 2016.Figures shown are for the trailing 12 months to Jun 30, 2026. Hover or tap a column for another year.20.0M
Show tableHide table
| Period | Shares outstanding |
|---|---|
| FY2016, ended Dec 31, 2016 | 25.9M |
| FY2017, ended Dec 31, 2017 | 25.5M |
| FY2018, ended Dec 31, 2018 | 24.8M |
| FY2019, ended Dec 31, 2019 | 24.1M |
| FY2020, ended Dec 31, 2020 | 23.4M |
| FY2021, ended Dec 31, 2021 | 22.8M |
| FY2022, ended Dec 31, 2022 | 22.1M |
| FY2023, ended Dec 31, 2023 | 21.5M |
| FY2024, ended Dec 31, 2024 | 20.9M |
| FY2025, ended Dec 31, 2025 | 20.3M |
| Trailing 12 months to Jun 30, 2026 (through Q2 FY2026) | 20.0M |
Buybacks and new shares
By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.Figures shown are for the trailing 12 months to Jun 30, 2026. Hover or tap a column for another year.Net: $752M more bought back than issued
Show tableHide table
| Period | Bought back | Paid to employees |
|---|---|---|
| FY2016, ended Dec 31, 2016 | $500M | $15.3M |
| FY2017, ended Dec 31, 2017 | $400M | $16.6M |
| FY2018, ended Dec 31, 2018 | $475M | $17.6M |
| FY2019, ended Dec 31, 2019 | $775M | $18.3M |
| FY2020, ended Dec 31, 2020 | $775M | $18.7M |
| FY2021, ended Dec 31, 2021 | $1000M | $19.6M |
| FY2022, ended Dec 31, 2022 | $1.10B | $19.7M |
| FY2023, ended Dec 31, 2023 | $900M | $17.9M |
| FY2024, ended Dec 31, 2024 | $850M | $20.0M |
| FY2025, ended Dec 31, 2025 | $800M | $22.5M |
| Trailing 12 months to Jun 30, 2026 (through Q2 FY2026) | $775M | $22.8M |
Revenue (TTM)
$4.13B
+6.9% YoY
Net income (TTM)
$906M
+9.1% YoY
Cash
$51.4M
−16.9% YoY
Total debt
$2.04B
−3.7% YoY
Valuation
At current price- Market Cap
- $33.6B
- P/E
- 37.1×
- Forward P/E
- —. Needs analyst estimates; not available from the current data provider
- Price / Sales
- 8.1×
- Price / Book
- 2617×
- EV / EBITDA
- 28.5×
Growth
Trailing 12 months- Revenue (TTM)
- $4.13B
- Revenue Growth YoY
- 6.9%
- Revenue CAGR 3Y
- 0.9%
- Revenue CAGR 5Y
- 5.5%
- EPS Growth YoY
- 12.5%
- Net Income Growth YoY
- 9.1%
Profitability
Trailing 12 months- Gross Margin
- 60.3%
- Operating Margin
- —
- Net Margin
- 21.9%
- FCF Margin
- 20.9%
- Return on Equity
- 7,062%
Earnings
Trailing 12 months- Net Income
- $906M
- EPS (diluted)
- $44.36
- EBITDA
- $1.25B
- Operating Income
- —
Balance Sheet
As of Jun 30, 2026- Cash and cash equivalents
- $51.4M
- Total Debt
- $2.04B
- Net Debt
- $1.99B
- Total Assets
- $3.67B
- Total Liabilities
- $3.66B
- Shareholders' Equity
- $12.8M
Cash Flow
Trailing 12 months- Operating Cash Flow
- $975M
- Capital Expenditure
- $111M
- Free Cash Flow
- $864M
Dividends and risk
Last 12 months- Dividend Yield
- 0.0%
- Dividend / Share
- $0.00
- Beta (5Y)
- 1.19
Every ratio is calculated from the company’s reported figures.
Strength
Revenue is up 6.9% year over year, at $4.13B.
Note
Net margin of 21.9% over the last 12 months.
Note
Net debt of $1.99B is 1.6× EBITDA.
Strength
Turns 20.9% of revenue into free cash flow.
Written by fixed rules from the reported figures, not by a person or an AI.
Latest report
Pro10-K for the fiscal year ended Dec 31, 2025 · filed Feb 6, 2026
The score and findings for the newest report are part of CoreStock Pro, coming soon. Every earlier report is free.
Score of each annual report
0 to 100 · 60 means nothing notable · tap a column for its details
2024 · 10-K64Mildly positive
64Mildly positive
10-K for the fiscal year ended Dec 31, 2024
Filed Feb 7, 2025 · Read the filing on EDGAR
- Sales rose 2% to $3.9 billion (3% in local currencies). Excluding the 2023 shipping delays that were recovered in early 2024, local-currency sales were flat.
- China stayed weak: local-currency sales fell 11% and Chinese segment profit fell 6%. Europe, other emerging markets and service revenue grew solidly.
- Gross margin improved to 60.1% from 59.2%, helped by pricing and cost savings. Operating cash flow held steady at $968 million.
- Buybacks were $850 million in 2024, with about $875 million planned for 2025. New risk language covers possible 60% US tariffs on Chinese goods.
Business momentum
Improving
“Net sales in U.S. dollars increased 2% in 2024 and decreased 3% in 2023.”
Outlook
Cautious
“However, many of our end-markets, including pharma/biopharmaceutical, food, and chemical, remain challenged after significant growth during the COVID-19 pandemic.”
Financial stress
Low
“Cash provided by operating activities totaled $968.3 million in 2024, compared to $965.9 million in 2023 and $859.1 million in 2022.”
Tone against the previous report
More positive
Red flags
None found in this report.
Positives
Better gross margin
“Gross profit as a percentage of net sales was 60.1% for 2024, 59.2% for 2023, and 58.9% for 2022.”
Strong growth in service revenue
“Service revenue (including spare parts) increased 7% in both U.S. dollars and local currencies in 2024”
Lab business returned to growth
“Net sales of our laboratory products and services, which represented approximately 56% of our total net sales in 2024, increased 6% in both U.S. dollars and local currencies during 2024.”
Concerns
China sales kept falling
“Overall, versus the prior year, we experienced a 1% decrease in emerging market local currency sales by destination during 2024, which included an 11% local currency sales decline in China”
Underlying growth was flat
“We estimate local currency net sales were flat in 2024 and decreased 1% in 2023 excluding the impact of the delayed shipments.”
Food retailing sales dropped sharply
“Net sales of our food retailing products and services, which represented approximately 5% of our total net sales in 2024, decreased 14% in both U.S. dollars and local currencies during 2024.”
New risks since the previous report
Possible steep US tariffs on Chinese imports
“Additionally, before taking office, President Trump pledged to impose 60% tariffs on all Chinese imports in his first year.”
Heavy reliance on China for production and profit
“our Chinese operations accounted for 16% of sales to external customers, 29% of total segment profit, and approximately 30% of our global production during 2024.”
New rules on artificial intelligence
“As we introduce AI and machine learning into our technology platform (as well as those of our customers through provision of our services), we could become subject to these new regulations, which may be difficult to comply with.”
Regulatory uncertainty after the Supreme Court ended the Chevron doctrine
“In June 2024, the U.S. Supreme Court overturned the Chevron doctrine, ending judicial deference to regulatory agencies.”
Biggest risks named
- Weak demand in China and US-China tariffs
- Prolonged slowdown in pharma, food and chemical customers
- Economic slowdown and inflation
- Currency swings in the Swiss franc, euro and renminbi
- Geopolitical conflicts and supply chain disruption
Artificial intelligence in this business: Mentioned
How the score adds up
| Starting point | 60 | |
| Business momentum | +6 | |
| Outlook | −2 | |
| Tone against the previous report | +2 | |
| Financial stress | 0 | |
| Red flags | 0 | |
| New risks | −2 | |
| Score | 64 | |
Written by AI (Claude Opus 5.5) from the report’s text. 13 of 13 quotes were found word for word in the filing; the rest are left out. Not investment advice.
All scored reports
| Period | Report | Filed | Score | Momentum | Red flags |
|---|---|---|---|---|---|
| 10-K | Feb 6, 2026 | Pro | |||
| 10-K | Feb 7, 2025 | 64 | Improving | None | |
| 10-K | Feb 9, 2024 | 47 | Weakening | 1 minor | |
| 10-K | Feb 10, 2023 | 62 | Improving | None | |
| 10-K | Feb 11, 2022 | 75 | Strong improvement | None | |
| 10-K | Feb 8, 2021 | 63 | Improving | None | |
| 10-K | Feb 7, 2020 | 62 | Improving | None | |
| 10-K | Feb 8, 2019 | 69 | Strong improvement | None | |
| 10-K | Feb 9, 2018 | 62 | Improving | 1 medium | |
| 10-K | Feb 2, 2017 | 66 | Improving | None |
How these scores work
An AI model reads the management discussion, risk factors and legal sections of each report and records what they say, quoting the filing word for word. Fixed rules then turn those findings into a score from 0 to 100, where 60 means nothing notable either way. A score describes the report, not whether the stock is a good investment, and the AI may know how things turned out later, which can colour older scores. Read the methodology
From the 10-Q for Q2 FY2026 (period ended Jun 30, 2026), filed Jul 31, 2026. View filings on SEC EDGAR